User profiles for "author:Helen McCarthy"

Helen O McCarthy

- Verified email at qub.ac.uk - Cited by 9924

Helen S McCarthy

- Verified email at keele.ac.uk - Cited by 966

Helen McCarthy

- Verified email at vu.edu.au - Cited by 488

Electrospinning of natural polymers for the production of nanofibres for wound healing applications

ADJ Bombin, NJ Dunne, HO McCarthy - Materials Science and …, 2020 - Elsevier
Wound healing is a highly regulated process composed of four overlapping phases:(1)
coagulation/haemostasis,(2) inflammation,(3) proliferation and (4) remodelling …

[HTML][HTML] RANK, RANKL and osteoprotegerin in bone biology and disease

HL Wright, HS McCarthy, J Middleton… - Current reviews in …, 2009 - Springer
Upon the discovery of RANK, RANKL and OPG in the late 1990s, their importance in the
maintenance of the skeletal structure and their dramatic role in bone disease were largely …

[HTML][HTML] MicroRNAs in pancreatic cancer: biomarkers, prognostic, and therapeutic modulators

AZ Daoud, EJ Mulholland, G Cole, HO McCarthy - BMC cancer, 2019 - Springer
A severe lack of early diagnosis coupled with resistance to most available therapeutic
options renders pancreatic cancer as a major clinical concern. The limited efficacy of current …

[HTML][HTML] Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

JA Burger, A Tedeschi, PM Barr, T Robak… - … England Journal of …, 2015 - Mass Medical Soc
Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …

Hydrogel‐forming microneedle arrays for enhanced transdermal drug delivery

RF Donnelly, TRR Singh, MJ Garland… - Advanced functional …, 2012 - Wiley Online Library
Unique microneedle arrays prepared from crosslinked polymers, which contain no drug
themselves, are described. They rapidly take up skin interstitial fluid upon skin insertion to …

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

CS Tam, S Opat, S D'Sa, W Jurczak… - Blood, The Journal …, 2020 - ashpublications.org
Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with
Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy …

[HTML][HTML] Identification and clonal characterisation of a progenitor cell sub-population in normal human articular cartilage

R Williams, IM Khan, K Richardson, L Nelson… - PloS one, 2010 - journals.plos.org
Background Articular cartilage displays a poor repair capacity. The aim of cell-based
therapies for cartilage defects is to repair damaged joint surfaces with a functional …

[HTML][HTML] Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

JA Burger, PM Barr, T Robak, C Owen, P Ghia… - Leukemia, 2020 - nature.com
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged≥ 65 years …

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

PM Barr, C Owen, T Robak, A Tedeschi… - Blood …, 2022 - ashpublications.org
We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily
Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant …

[HTML][HTML] Hydrogel-forming microneedles prepared from “super swelling” polymers combined with lyophilised wafers for transdermal drug delivery

RF Donnelly, MTC McCrudden, A Zaid Alkilani… - PloS one, 2014 - journals.plos.org
We describe, for the first time, hydrogel-forming microneedle arrays prepared from “super
swelling” polymeric compositions. We produced a microneedle formulation with enhanced …